References
- Auclair C, Kelly P A, Coy D H, Schally A V, Labrie F. Potent inhibitory activity of (D-Leu6, des-Gly-NH210) LHRH ethylamide on LH/hCG and PRL receptor levels in the rat. Endocrinology 1977; 101: 1890–1893
- Auclair C, Kelly P A, Labrie F, Coy D H, Schally A V. Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist or human chorionic gonadotropin. Biochem Biophy Res Commun 1977; 76: 855–862
- Auclair C, Stern M, Givner M L. LHRH and analogues as potential therapy for benign prostatic hyperplasia and hormone-dependent cancers. Arch Androl 1981; 7: 237–244
- Belanger A, Auclair C, Ferland L, Labrie F. Time-course of the effects of treatment with a potent LHRH agonist on testicular steroidogenesis and gonadotropin receptor levels in the adult rat. J Steroid Biochem 1980; 13: 191–196
- Bergquist C, Nillius S J, Bergh T, Skarin G, Wide L. Inhibitory effects of gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrin 1979; 91: 601–608
- Givner M L, Dvornik D. Inhibition of testosterone biosynthesis by medrogestone. Experientia 1972; 28: 1105–1106
- Givner M L, Jagarinec N. Inhibition of prostatic dihydrotestosterone formation by medrogestone. J Steroid Biochem (Abstr.) 1974; 5: 352
- Hsueh A JW, Erickson G F. Extra-pituitary inhibition of testicular function by luteinizing hormone-releasing hormone. Nature 1979; 281: 66–67
- Jagarinec N, Givner M L. Effect of medrogestone on conversions of pregnenolone and 17α-hydroxypregnenolone in rat testis. Arch Androl 1981; 7: 35–37
- Jagarinec N, Givner M L. Inhibition of testosterone metabolism by medrogestone in rat ventral prostate in vivo and in vitro. Arch Androl 1981; 7: 39–44
- Jones D, Cameron E HD, Griffiths K. Steroid metabolism by human breast tumors. Biochem J 1970; 116: 919–921
- Paulson D F, Kane R D. Medrogestone: a prospective study in the pharmaceutical management of benign prostatic hypoplasia. J Urol 1975; 113: 811–815
- Rangno R E, McLeod P J, Ruedy J, Ogilvie R I. Treatment of benign prostatic hypertrophy with medrogestone. Clin Pharmacol Ther 1971; 12: 658–665
- Revesz C, Chappel C I. Biological activity of medrogestone: a new orally active progestin. J Reprod Fertil 1966; 12: 473–487
- Sandow J, von Rochenberg W, Jerzabek G, Stoll W. Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril 1978; 30: 205–209
- Tan S Y, Antonipillai I, Murphy B EP. Inhibition of testosterone metabolism in the human prostate. J Clin Endocrinol Metab 1974; 39: 936–941
- Thijssen J HH, Poortman J, Schwarz F, De Waard F. Postmenopausal estrogen production, with special reference to patients with mammary carcinoma. Hormone Res 1975; 3: 45–62
- Waterman E A, Benson R C. Medrogestone therapy in advanced endometrial adeno-carcinoma. Obstet Gynec 1967; 30: 626